- Policy
- Remdesivir to promote domestic clinical trials for COVID-19
- by Lee, Tak-Sun Feb 27, 2020 06:33am
- Gilead developed the Ebola treatment 'Remdesivir' in preparation for a clinical trial in Korea. The MFDS plans to review the Phase III clinical trial plan from Gilead promptly. Eui-Kyung Lee, the Minister of the MFDS explained on the 25th at the regular briefing on the COVID-19 Central Disaster and Safety Headquarters, "COVID-19 drugs a
- Company
- Obesity market surpassed ￦100 billion in 10 years
- by An, Kyung-Jin Feb 27, 2020 06:33am
- Last year, 'Saxenda', which had gained popularity through going viral with 'Gangnam injection' and 'antiobestic injection', evaluated the domestic obesity treatment market. After 3rd quarterly sales, it gained the top spot, and its market share soared to almost one-third of the entire market. In the wake of the Saxenda, the total market size
- Company
- COVID-19 closes LS Tower, GSK-Janssen to work from home
- by Jung, Hye-Jin Feb 27, 2020 06:33am
- As an office worker working at LS Yongsan Tower, located in Yongsan-gu, Seoul, was confirmed have been infected with COVID-19, pharmaceutical company offices housed at the tower told their employees to work from home. The authorities of Yongsan-gu announced on Feb. 25 the LS Yongsan Tower would be closed as an office worker working on th
- Company
- Next gen Keytruda and Tagrisso skyrocket up the market rank
- by Chon, Seung-Hyun Feb 27, 2020 06:32am
- A next generation anticancer therapy developed by a multinational pharmaceutical company has shuffled through the best-selling pharmaceuticals rank in Korea. Four years since the launch, Keytruda has generated over 100 billion won a year. Tagrisso and Opdivo also showed a steep surge in growth. Pharmaceutical market research firm IQVIA on Fe
- Policy
- Betmiga lowers pricing with PVA, Tazime keeps original price
- by Kim, Jung-Ju Feb 27, 2020 06:32am
- Hanmi Pharmaceutical’s bacterial blood infection and meningitis treatment Tazime 2 g injection has been exempted from automatic pricing reduction as its competing item is removed from the tentative reimbursement listing. The price of Astellas Pharma Korea’s blockbuster drug Betmiga PR tablet would be lowered from Mar 1 due to price-volume
- Company
- GSK-Pfizer JV launch in Korea put off indefinitely
- by An, Kyung-Jin Feb 26, 2020 06:18pm
- Pfizer Pharmaceutical Korea and GlaxoSmithKline Korea’s (GSK Korea) Consumer Healthcare Joint Venture launch schedule in Korea took a sharp turn unexpectedly. . Pharmaceutical industry source reported Korean offices of Pfizer and GSK have announced indefinite postponement of launching the consumer healthcare division joint venture. A
- 8 years since launch, oral JAK inhibitors topping the market
- by Won, jong-hyuck Feb 26, 2020 06:30am
- Starting from rheumatoid arthritis to psoriatic arthritis, ulcerative colitis, atopic dermatitis and alopecia areata, oral Janus kinase (JAK) inhibitors expanding indications are heating up the prescription competition among themselves. For decades, autoimmune disease area was covered by biological medicines (injection) like tumor necrosis f
- Company
- Sales activities messed up by COVID-19 crisis
- by Chon, Seung-Hyun Feb 26, 2020 06:29am
- Pharmaceutical companies have already been struggling with earnings this year. Concerned about COVID-19 infection, people are reluctant to visit medical institutions, and their business activities for medical staff are virtually suspended. According to UBIST on the 25th, the total outpatient prescription amount last month was ￦1.25 tril
- Policy
- National Assembly also shocked by COVID-19
- by Lee, Jeong-Hwan Feb 26, 2020 06:29am
- Parliament and politicians were also shocked by COVID-19. Recently, the plenary session was urgently canceled as the delegation of the debate held at the congress hall in the parliament building was confirmed by COVID-19, and a 24 hour closure measure was established for defense. Representative Jae-cheol Shim and a member Jeon Hee-kyung
- Company
- Cenobamate, received the grand prize for KNDA
- by Lee, Seok-Jun Feb 26, 2020 06:29am
- SK Biopharmaceuticals announced on the 24th that a new epilepsy drug, Cenobamate (USA Product Name: Xcopri), was selected as the grand prize for Korea New Drug Award (KNDA). This year's 21st KNDA is the only award in the domestic and international pharmaceutical biohealth industry new drug development sector, sponsored by the private secto
